source
- Roche CEO says stance on $1.5B Poseida acquisition unchanged despite dropping one CAR-T programRoche bought Poseida in 2024 for $1.5 billion to secure its off-the-shelf CAR-T platform and strengthen its cell-therapy portfolio. During the third-quarter earnings call, the company said it has…
- Roche talks up Phase 3 success rate as it unveils pipeline cutsWhere other European pharmas — notably Novartis, Novo and AstraZeneca — have suffered huge late-stage clinical failures this summer, Roche is feeling rather smug. CEO Thomas Schinecker said ...Endpoints · 40m ago↗ source